PANDA: The Newest Product at EpiVax

PANDA: The Newest Product at EpiVax

Revolutionizing Risk Assessment: Generic Peptide Drugs and Their Impurities EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and...
EpiVax Oncology Completes a $1.2M Bridge Financing

EpiVax Oncology Completes a $1.2M Bridge Financing

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate...